156 related articles for article (PubMed ID: 31764064)
1. Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management.
Penel N; Ryckewaert T; Le Deley MC
Am J Clin Oncol; 2019 Dec; 42(12):958. PubMed ID: 31764064
[No Abstract] [Full Text] [Related]
2. Desmoid tumours stalled by sorafenib.
Wrighton KH
Nat Rev Clin Oncol; 2019 Apr; 16(4):209. PubMed ID: 30664677
[No Abstract] [Full Text] [Related]
3. Treatment of Orbital Desmoid-type Fibromatosis With Sorafenib.
Downie EM; Amend CE; Miranda A; Burkat CN
Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):e144-e147. PubMed ID: 35470290
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.
Robles J; Keskinyan VS; Thompson M; Davis JT; Mater DV
Pediatr Hematol Oncol; 2020 Aug; 37(5):445-449. PubMed ID: 32129687
[No Abstract] [Full Text] [Related]
5. [Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
Penel N; Ryckewaert T; Orbach D
Bull Cancer; 2020 Mar; 107(3):375-380. PubMed ID: 31812284
[TBL] [Abstract][Full Text] [Related]
6. Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Gounder MM; Lefkowitz RA; Keohan ML; D'Adamo DR; Hameed M; Antonescu CR; Singer S; Stout K; Ahn L; Maki RG
Clin Cancer Res; 2011 Jun; 17(12):4082-90. PubMed ID: 21447727
[TBL] [Abstract][Full Text] [Related]
7. Desmoid-type fibromatosis: toward a holistic management.
Penel N; Kasper B; van Der Graaf WTA
Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
[No Abstract] [Full Text] [Related]
9. Extra-abdominal aggressive fibromatosis treated with meloxicam and sorafenib: An encouraging option.
Sari M
J Cancer Res Ther; 2020; 16(4):900-902. PubMed ID: 32930137
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of mammary desmoid-type fibromatosis: which benefit?
Scheer L; Lodi M; Molière S; Kurtz JE; Mathelin C
World J Surg Oncol; 2017 Apr; 15(1):86. PubMed ID: 28420393
[TBL] [Abstract][Full Text] [Related]
11. Current management and recent progress in desmoid tumors.
Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
[TBL] [Abstract][Full Text] [Related]
12. Desmoid tumors: who, when and how to treat?
Mikhael R; Smith M; Tzanis D; Watson S; Miah AB; Bonvalot S
Curr Opin Oncol; 2022 Jul; 34(4):335-341. PubMed ID: 35837705
[TBL] [Abstract][Full Text] [Related]
13. Extra-abdominal desmoid tumor in the subcutis of the thigh.
Fujisawa Y; Sugita S; Kawachi Y; Otsuka F
J Dermatol; 2011 Aug; 38(8):810-2. PubMed ID: 21352329
[No Abstract] [Full Text] [Related]
14. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
15. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.
Braggio D; Koller D; Jin F; Siva N; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Strohecker AM; Lev D; Pollock RE
Cancer; 2019 Aug; 125(15):2693-2703. PubMed ID: 30980399
[TBL] [Abstract][Full Text] [Related]
16. Desmoid Fibromatosis: Management in an Era of Increasing Options.
Ratan R; Roland CL; Bishop AJ
Curr Oncol Rep; 2021 Mar; 23(4):41. PubMed ID: 33719012
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
18. In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition.
Schut AW; Vriends ALM; Sacchetti A; Timbergen MJM; Alman BA; Al-Jazrawe M; Grünhagen DJ; Verhoef C; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2022 Jul; 48(7):1527-1535. PubMed ID: 35221159
[TBL] [Abstract][Full Text] [Related]
19. The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.
Santti K; Beule A; Rönty M; Ihalainen H; Tarkkanen M; Blomqvist C
Acta Oncol; 2019 Jun; 58(6):897-900. PubMed ID: 30905251
[No Abstract] [Full Text] [Related]
20. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
Tsukamoto S; Takahama T; Mavrogenis AF; Tanaka Y; Tanaka Y; Errani C
Musculoskelet Surg; 2023 Mar; 107(1):7-18. PubMed ID: 35150408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
